ABBOTT LABORATORIES — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Abbott reported Q3 2026 comparable sales growth of 7.0% ($13.0B total sales, 14.5% reported) and adjusted diluted EPS of $1.42. The company reaffirmed full-year 2026 adjusted EPS guidance, tightening the range to $5.50–$5.55 (midpoint ~$5.53). Major driver: March 23, 2026 acquisition of Exact Sciences ($706M sales contribution in 9M26); diagnostics segment surged 46.7% reported, 6.4% comparable. Legal settlements (~$670M pre-tax for Gill/NEC cases; ~$400M for DOJ/qui tam resolution) reduced reported earnings significantly but excluded from adjusted metrics.
Why this rating
Routine quarterly earnings; 7% organic growth and guidance reaffirmation are ordinary for a $232B company. Exact Sciences integration is ongoing but anticipated. Legal settlements are material in absolute terms (~$1.1B pre-tax) but represent <0.5% of annual revenue and were previously flagged. No trajectory change.
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.